Animal experiments consistently show that young blood components can counteract ageing and that removing old factors is at least equally important. These are biologically plausible and causally supported findings in mouse models, but the research is still at an early stage: clinical trials in humans are largely absent. Anyone paying today for a commercial young blood transfusion is buying a product without clinical evidence and with unknown safety risks.
Young blood or plasma exchange is a concept in which the circulation of older individuals is connected to, or influenced by, blood from young individuals, with the aim of counteracting ageing. The idea originates from so-called parabiosis experiments in mice: by surgically connecting the circulatory system of a young mouse to that of an old mouse, the organs of the old mouse appeared to rejuvenate noticeably. Multiple tissues showed these effects, suggesting that rejuvenating factors present in blood decline with age. This has been demonstrated in animal experiments and is considered causal in those models, but it does not yet constitute clinical evidence in humans.
A key question then arose: is it sufficient to add young blood, or is it at least as important to remove harmful factors from old blood? More recent studies in mice suggest that the old blood environment is dominant: exposing young muscle cells to old blood substantially accelerates their ageing. This has led to an alternative approach, namely diluting or removing aged plasma proteins through plasma exchange, without the need for donor blood. Animal experiments show that this recalibrates the protein profile in the blood to a younger state. Some researchers consider this approach more promising than simply injecting young plasma.
In mouse models of Alzheimer's disease, young plasma produced positive results: loss of synaptic proteins was partly restored, and spatial memory and associative memory improved. Notably, however, the characteristic amyloid plaques of Alzheimer's disease did not decrease. Whether these findings translate to humans remains an open question and is being investigated in early clinical studies. Young bone marrow transplantation also showed positive effects on cognition in mice, with preservation of brain synapses and less inflammation in brain immune cells, but translation to humans is speculative for now.
Set against this laboratory and animal research is commercial practice: multiple companies are already selling 'young blood transfusions' to people. There is no evidence of efficacy or safety for this in the available scientific literature. This is a concrete risk signal: products are being offered without clinical evidence. A publication about Yuvan Research, a company with a commercial interest, bases conclusions about ageing reversal partly on anecdotal evidence, the weakest form of scientific evidence. Claims of this kind warrant extra caution, precisely because of the commercial interest of those making them.
In summary, this field is in a phase where animal and laboratory research consistently shows interesting results, but where controlled clinical studies in humans are largely absent. The most well-supported insight is that both adding young factors and removing old factors may play a role, and that the old blood environment in itself already appears to accelerate ageing. For humans at this time: there is no clinical evidence that commercial young blood transfusions work, and the safety risks are unknown.
All claims are based on animal and laboratory studies (mouse models of parabiosis, Alzheimer's disease, and bone marrow transplantation) and one publication with anecdotal evidence from a commercial party. No randomised controlled trials in humans are available in the provided sources. PMIDs: 33197235, 25327899, 41998143, 28384033, 38842660, 32054965, 39672207, 37424351.